vs
Side-by-side financial comparison of ADAMAS TRUST, INC. (ADAM) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $43.2M, roughly 1.3× ADAMAS TRUST, INC.). ADAMAS TRUST, INC. runs the higher net margin — 124.0% vs -83.0%, a 207.0% gap on every dollar of revenue. On growth, ADAMAS TRUST, INC. posted the faster year-over-year revenue change (61.6% vs 36.9%). Over the past eight quarters, ADAMAS TRUST, INC.'s revenue compounded faster (55.5% CAGR vs 48.5%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
ADAM vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.2M | $57.3M |
| Net Profit | $53.5M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | — | -82.2% |
| Net Margin | 124.0% | -83.0% |
| Revenue YoY | 61.6% | 36.9% |
| Net Profit YoY | 270.5% | -9.6% |
| EPS (diluted) | $0.45 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.2M | $57.3M | ||
| Q3 25 | $36.6M | $51.3M | ||
| Q2 25 | $36.4M | $48.5M | ||
| Q1 25 | $33.1M | $32.7M | ||
| Q4 24 | $26.7M | $41.8M | ||
| Q3 24 | $20.2M | $33.3M | ||
| Q2 24 | $19.0M | $29.1M | ||
| Q1 24 | $17.9M | $26.0M |
| Q4 25 | $53.5M | $-47.5M | ||
| Q3 25 | $44.8M | $-52.9M | ||
| Q2 25 | $8.5M | $-46.6M | ||
| Q1 25 | $42.2M | $-49.5M | ||
| Q4 24 | $-31.4M | $-43.3M | ||
| Q3 24 | $42.8M | $-43.6M | ||
| Q2 24 | $-15.6M | $-32.3M | ||
| Q1 24 | $-57.9M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | 11.7% | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | -119.0% | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | -124.7% | -139.2% | ||
| Q1 24 | -448.8% | -538.7% |
| Q4 25 | 124.0% | -83.0% | ||
| Q3 25 | 122.5% | -103.1% | ||
| Q2 25 | 23.4% | -96.1% | ||
| Q1 25 | 127.4% | -151.4% | ||
| Q4 24 | -117.5% | -103.6% | ||
| Q3 24 | 211.7% | -131.2% | ||
| Q2 24 | -81.9% | -110.9% | ||
| Q1 24 | -324.1% | -544.4% |
| Q4 25 | $0.45 | $-0.73 | ||
| Q3 25 | $0.36 | $-0.82 | ||
| Q2 25 | $-0.04 | $-0.75 | ||
| Q1 25 | $0.33 | $-0.81 | ||
| Q4 24 | $-0.46 | $-0.71 | ||
| Q3 24 | $0.36 | $-0.73 | ||
| Q2 24 | $-0.29 | $-0.55 | ||
| Q1 24 | $-0.75 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $210.3M | $388.9M |
| Total DebtLower is stronger | $735.8M | — |
| Stockholders' EquityBook value | $1.4B | $139.1M |
| Total Assets | $12.6B | $480.2M |
| Debt / EquityLower = less leverage | 0.52× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $210.3M | $388.9M | ||
| Q3 25 | $185.3M | $416.1M | ||
| Q2 25 | $160.4M | $291.0M | ||
| Q1 25 | $177.1M | $314.5M | ||
| Q4 24 | $167.4M | $320.6M | ||
| Q3 24 | $195.1M | $298.4M | ||
| Q2 24 | $235.5M | $319.1M | ||
| Q1 24 | $226.9M | $201.2M |
| Q4 25 | $735.8M | — | ||
| Q3 25 | $766.6M | — | ||
| Q2 25 | $653.0M | — | ||
| Q1 25 | $654.4M | — | ||
| Q4 24 | $573.2M | — | ||
| Q3 24 | $699.4M | — | ||
| Q2 24 | $800.7M | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $1.4B | $139.1M | ||
| Q3 25 | $1.4B | $148.8M | ||
| Q2 25 | $1.4B | $-11.9M | ||
| Q1 25 | $1.4B | $18.9M | ||
| Q4 24 | $1.4B | $21.7M | ||
| Q3 24 | $1.4B | $11.2M | ||
| Q2 24 | $1.4B | $39.3M | ||
| Q1 24 | $1.5B | $61.6M |
| Q4 25 | $12.6B | $480.2M | ||
| Q3 25 | $12.4B | $506.9M | ||
| Q2 25 | $10.6B | $372.7M | ||
| Q1 25 | $10.0B | $386.7M | ||
| Q4 24 | $9.2B | $392.3M | ||
| Q3 24 | $8.9B | $363.6M | ||
| Q2 24 | $8.2B | $381.8M | ||
| Q1 24 | $7.4B | $258.7M |
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.55× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.56× | — | ||
| Q1 24 | 0.67× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $134.0M | $-25.4M |
| Free Cash FlowOCF − Capex | $125.9M | — |
| FCF MarginFCF / Revenue | 291.6% | — |
| Capex IntensityCapex / Revenue | 18.9% | — |
| Cash ConversionOCF / Net Profit | 2.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $134.0M | $-25.4M | ||
| Q3 25 | $6.9M | $-26.6M | ||
| Q2 25 | $39.2M | $-23.3M | ||
| Q1 25 | $25.8M | $-40.4M | ||
| Q4 24 | $14.1M | $-18.8M | ||
| Q3 24 | $-922.0K | $-25.2M | ||
| Q2 24 | $-993.0K | $-29.1M | ||
| Q1 24 | $-13.1M | $-40.7M |
| Q4 25 | $125.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-10.6M | — | ||
| Q3 24 | $-8.6M | — | ||
| Q2 24 | $-8.6M | — | ||
| Q1 24 | $-19.1M | — |
| Q4 25 | 291.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -39.6% | — | ||
| Q3 24 | -42.3% | — | ||
| Q2 24 | -44.9% | — | ||
| Q1 24 | -107.0% | — |
| Q4 25 | 18.9% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 92.3% | — | ||
| Q3 24 | 37.7% | — | ||
| Q2 24 | 39.7% | — | ||
| Q1 24 | 33.5% | — |
| Q4 25 | 2.50× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 4.59× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.02× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADAM
| Other | $19.6M | 45% |
| Constructive Loans LLC | $14.4M | 33% |
| Multifamily | $9.1M | 21% |
RYTM
Segment breakdown not available.
